BR9505815A - Composto processos para a preparação do mesmo e para obter um efeito anti-isquêmico e anti-hipertensivo e para produzir atividade agonista 2 pré-sináptica e antagonista 1 pós-sináptica em um paciente e composição farmacêutica - Google Patents

Composto processos para a preparação do mesmo e para obter um efeito anti-isquêmico e anti-hipertensivo e para produzir atividade agonista 2 pré-sináptica e antagonista 1 pós-sináptica em um paciente e composição farmacêutica

Info

Publication number
BR9505815A
BR9505815A BR9505815A BR9505815A BR9505815A BR 9505815 A BR9505815 A BR 9505815A BR 9505815 A BR9505815 A BR 9505815A BR 9505815 A BR9505815 A BR 9505815A BR 9505815 A BR9505815 A BR 9505815A
Authority
BR
Brazil
Prior art keywords
synaptic
ischemic
agonist
patient
post
Prior art date
Application number
BR9505815A
Other languages
English (en)
Portuguese (pt)
Inventor
Jean-Pierre Geerts
Genevieve Motte
Edmond Differding
Jean-Pierre Henichart
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of BR9505815A publication Critical patent/BR9505815A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9505815A 1994-12-14 1995-12-13 Composto processos para a preparação do mesmo e para obter um efeito anti-isquêmico e anti-hipertensivo e para produzir atividade agonista 2 pré-sináptica e antagonista 1 pós-sináptica em um paciente e composição farmacêutica BR9505815A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9425211.1A GB9425211D0 (en) 1994-12-14 1994-12-14 Substituted 1H-imidazoles

Publications (1)

Publication Number Publication Date
BR9505815A true BR9505815A (pt) 1998-01-06

Family

ID=10765918

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9505815A BR9505815A (pt) 1994-12-14 1995-12-13 Composto processos para a preparação do mesmo e para obter um efeito anti-isquêmico e anti-hipertensivo e para produzir atividade agonista 2 pré-sináptica e antagonista 1 pós-sináptica em um paciente e composição farmacêutica

Country Status (26)

Country Link
US (1) US5658938A (OSRAM)
EP (1) EP0717037A1 (OSRAM)
JP (1) JPH08208622A (OSRAM)
KR (1) KR960022474A (OSRAM)
CN (1) CN1054376C (OSRAM)
AR (1) AR002257A1 (OSRAM)
AU (1) AU693614B2 (OSRAM)
BG (1) BG63043B1 (OSRAM)
BR (1) BR9505815A (OSRAM)
CA (1) CA2165133A1 (OSRAM)
CZ (1) CZ327195A3 (OSRAM)
EE (1) EE9500064A (OSRAM)
FI (1) FI955927A7 (OSRAM)
GB (1) GB9425211D0 (OSRAM)
HU (1) HUT73980A (OSRAM)
IL (1) IL116325A (OSRAM)
IS (1) IS4311A (OSRAM)
MX (1) MX9505063A (OSRAM)
NO (1) NO305316B1 (OSRAM)
NZ (1) NZ280646A (OSRAM)
PL (1) PL311736A1 (OSRAM)
RO (1) RO113346B1 (OSRAM)
RU (1) RU2156239C2 (OSRAM)
SK (1) SK155095A3 (OSRAM)
TW (1) TW303362B (OSRAM)
ZA (1) ZA9510554B (OSRAM)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
ZA981080B (en) * 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
US20030073850A1 (en) * 1998-08-07 2003-04-17 Altenbach Robert J. 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
US6503935B1 (en) * 1998-08-07 2003-01-07 Abbott Laboratories Imidazoles and related compounds as α1A agonists
US6388090B2 (en) 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
JP2003532712A (ja) 2000-05-08 2003-11-05 オリオン コーポレーション α２アドレナリン作用活性を有する新規な多環式インダニルイミダゾール
TW200930291A (en) * 2002-04-29 2009-07-16 Bayer Cropscience Ag Pesticidal heterocycles
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
FI20022007A0 (fi) * 2002-11-08 2002-11-08 Juvantia Pharma Ltd Oy Oromukosaalinen valmiste ja menetelmä sen valmistamiseksi
FI20022159A0 (fi) * 2002-12-05 2002-12-05 Orion Corp Uusia farmaseuttisia yhdisteitä
JP2009524618A (ja) * 2006-01-27 2009-07-02 エフ．ホフマン−ラ ロシュ アーゲー Ｃｎｓ障害の処置における２−イミダゾールの使用
DE602007005671D1 (de) * 2006-10-19 2010-05-12 Hoffmann La Roche Aminomethyl-2-imidazole mit affinität zu mit dem trace-amin assoziierten rezeptoren
AU2007312390B2 (en) * 2006-10-19 2013-03-28 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
AU2007316257A1 (en) * 2006-11-02 2008-05-08 F. Hoffmann-La Roche Ag Substituted 2-imidazoles as modulators of the trace amine associated receptors
WO2008058867A2 (en) * 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
KR101189348B1 (ko) * 2006-12-13 2012-10-09 에프. 호프만-라 로슈 아게 미량 아민 결합 수용체(ｔａａｒ)에 대한 리간드로서의 신규한 2-이미다졸
US20080146523A1 (en) * 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
ES2510546T3 (es) 2007-02-02 2014-10-21 F. Hoffmann-La Roche Ag Nuevas 2-aminooxazolinas como ligandos TAAR1 para trastornos del SNC
EP2398776A1 (en) * 2007-02-13 2011-12-28 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
BRPI0807961A2 (pt) * 2007-02-13 2017-05-16 Pharmacopeia Llc agonista de alfa2c adrenorreceptor funcionalmente seletivos.
CA2678069A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
MX2009008465A (es) * 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
CN101687812A (zh) 2007-07-02 2010-03-31 弗·哈夫曼-拉罗切有限公司 对痕量胺相关受体(taar)具有良好亲和性的2-咪唑啉化合物
KR101150628B1 (ko) * 2007-07-03 2012-05-31 에프. 호프만-라 로슈 아게 4-이미다졸린 및 항우울제로서 이의 용도
CN101765587A (zh) * 2007-07-27 2010-06-30 弗·哈夫曼-拉罗切有限公司 作为taar配体的2-氮杂环丁烷甲胺类和2-吡咯烷甲胺类
AU2008281877A1 (en) * 2007-08-02 2009-02-05 F. Hoffmann-La Roche Ag The use of benzamide derivatives for the treatment of CNS disorders
KR101167773B1 (ko) * 2007-08-03 2012-07-24 에프. 호프만-라 로슈 아게 Ｔａａｒ１ 리간드로서의 피리딘카복스아마이드 및 벤즈아마이드 유도체
CL2008003553A1 (es) * 2007-12-05 2009-11-27 Grindeks Jsc Proceso para preparar atipamezol o clorhidrato de 5-(2-etil-2,3-dihidro-1h-inden-2-il)-1h-imidazol: y loa compuestos intermediarios considerados en el proceso
WO2009105504A2 (en) 2008-02-21 2009-08-27 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
US8242153B2 (en) * 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
AU2009273324A1 (en) * 2008-07-24 2010-01-28 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl derivatives
EP2323734A1 (en) * 2008-08-04 2011-05-25 Schering Corporation Cyclopropylchromene derivatives as modulators of the alpha-2c receptor
TW201026691A (en) 2008-10-07 2010-07-16 Schering Corp Biaryl spiroaminooxazoline analogues as alpha2C adrenergic receptor modulators
US20100311798A1 (en) * 2009-06-05 2010-12-09 Decoret Guillaume 2-aminooxazolines as taar1 ligands
US8354441B2 (en) * 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8673950B2 (en) 2010-11-02 2014-03-18 Hoffmann-Laroche Inc. Dihydrooxazol-2-amine derivatives
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
KR101631003B1 (ko) 2012-01-12 2016-06-15 에프. 호프만-라 로슈 아게 미량 아민 결합 수용체(taar)로서 헤테로환형 유도체
EA026062B1 (ru) 2012-09-14 2017-02-28 Ф. Хоффманн-Ля Рош Аг Производные пиразолкарбоксамида в качестве модуляторов рецепторов следовых аминов (taar) для применения при лечении различных расстройств, таких как депрессия, диабет и болезнь паркинсона
HK1206714A1 (en) * 2012-09-17 2016-01-15 霍夫曼-拉罗奇有限公司 Triazole carboxamide derivatives
WO2015165085A1 (en) 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
KR101894681B1 (ko) 2014-08-27 2018-09-04 에프. 호프만-라 로슈 아게 Taar 리간드로서의 치환된 아제티딘 유도체
CN106470994B (zh) 2014-08-27 2019-09-24 豪夫迈·罗氏有限公司 用于治疗cns疾病的取代的吡嗪并[2,1-a]异喹啉衍生物
HUE055651T2 (hu) * 2016-03-17 2021-12-28 Fmc Corp Eljárás S-enantiomer konvertálására racém formájává
MY195528A (en) 2016-03-17 2023-01-30 Hoffmann La Roche 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar
CN116496261B (zh) * 2023-03-09 2025-06-27 中国人民解放军军事科学院军事医学研究院 4-(1h)-咪唑类衍生物及其医药用途
CN118684628B (zh) * 2024-05-20 2025-06-17 中国人民解放军军事科学院军事医学研究院 取代二氢茚基咪唑类化合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6048972A (ja) * 1983-08-25 1985-03-16 Dai Ichi Seiyaku Co Ltd テトラヒドロナフタレン誘導体
GB2167408B (en) * 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB8626287D0 (en) * 1986-11-04 1986-12-03 Ucb Sa Substituted 1h-imidazoles
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5151526A (en) * 1990-10-11 1992-09-29 The United States Of America As Represented By The Secretary Of The Army 4-[1-(1-naphthalenyl)ethyl]-1H-imidazole, method of making and use as an anesthetic
JPH04210680A (ja) * 1990-12-01 1992-07-31 Nissan Chem Ind Ltd イミダゾール誘導体および植物生長調節剤
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles

Also Published As

Publication number Publication date
CZ327195A3 (en) 1996-07-17
EP0717037A1 (fr) 1996-06-19
EE9500064A (et) 1996-06-17
FI955927A0 (fi) 1995-12-11
RO113346B1 (ro) 1998-06-30
CN1133837A (zh) 1996-10-23
US5658938A (en) 1997-08-19
MX9505063A (es) 1997-01-31
RU2156239C2 (ru) 2000-09-20
AR002257A1 (es) 1998-03-11
AU693614B2 (en) 1998-07-02
NZ280646A (en) 1996-08-27
AU4036895A (en) 1996-06-20
KR960022474A (ko) 1996-07-18
GB9425211D0 (en) 1995-02-15
TW303362B (OSRAM) 1997-04-21
HU9503549D0 (en) 1996-02-28
CN1054376C (zh) 2000-07-12
IL116325A (en) 1999-10-28
JPH08208622A (ja) 1996-08-13
BG63043B1 (bg) 2001-02-28
PL311736A1 (en) 1996-06-24
ZA9510554B (en) 1996-06-13
FI955927L (fi) 1996-06-15
HUT73980A (en) 1996-10-28
FI955927A7 (fi) 1996-06-15
CA2165133A1 (en) 1996-06-15
IS4311A (is) 1996-06-15
NO305316B1 (no) 1999-05-10
NO955034D0 (no) 1995-12-12
BG100208A (bg) 1996-07-31
NO955034L (no) 1996-06-17
IL116325A0 (en) 1996-03-31
SK155095A3 (en) 1997-02-05

Similar Documents

Publication Publication Date Title
BR9609353A (pt) Composição farmacêutica conveniente para administração em humanos processo para melhorar sintomas de uma desordem proliferativa celular e compostos
FI903845A7 (fi) Reniini-inhibiittoreita, menetelmä niiden valmistamiseksi ja niiden käyttö lääkkeissä
DK0723774T3 (da) Anvendelse af en antagonist for CGRP i en kosmetisk, farmaceutisk eller dermatologisk sammensætning og den opnåede sammensæ
BR9611410A (pt) Método e composição farmacêutica para regular a concentração de lipídios
DE69801045D1 (de) Pharmazeutische zusammensetzung zur oralen verabreichung von einem n-piperidin-3-pyrazolcarboxamid-derivat, dessen salzen und deren solvaten
BR9510302A (pt) Forma de dosagem farmacêutical de liberação controlada método para tratamento sintomático da tosse método para preparar uma forma de dosagem farmacêutica de liberação controlada composição para uso no tratamento sintomático da tosse e aplicação de uma forma dosagem de moguisteina de liberação controlada
IT9067924A0 (it) Composizione e metodo per la riduzione dell'appetito
IT1254323B (it) Perfezionata composizione biologica in particelle e procedimento per la sua produzione
FI891590A7 (fi) Ihoa kosteuttava koostumus ja menetelmä sen valmistamiseksi
PT929516E (pt) Derivados da benzamidina e sua utilizacao em composicoes farmaceuticas com efeito antagonista da ltb4
NO20016068L (no) Anvendelse av oksypurin-nukleosider for fremstilling av et farmasöytisk preparat for redusering av inflammasjon i et dyr
DE69522188D1 (de) Verwendung von Substanz P Antagonist im pharmazeutischer Zusammensetzung
BR9206950A (pt) Composição farmacêutica e processo para sua preparação
DE4495520T1 (de) Verfahren und pharmazeutische Zusammensetzung zum zielgerichten Anwenden von Wirkstoffen
FI973040L (fi) Rasemointimenetelmä käytettäväksi levobupivakaiinin ja siihen läheisesti liittyvien piperidiinikarboksanilidipuudutusaineiden valmistuksessa
FI945694L (fi) Substituoiden triatsolin sulfaattisuola, sen farmaseuttisia koostumuksia ja niiden käyttö terapiassa
ITMI922779A0 (it) Antagonisti delle tachichinine, procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche
FI902901A7 (fi) Dibentsoli/1,5/dioksosiini-5-oni-johdannaisia, niiden käyttö lääkeaineissa ja menetelmä niiden valmistamiseksi
NO974057L (no) Bisykliske takykinin-antagonister, fremstilling derav og deres anvendelse i farmasöytisk sammensetning
GB2221464B (en) Oxaza heterocycles and their use in pharmaceutical compositions
IT1142304B (it) Derivati dell'indano loro preparazione e loro applicazione in terapeutica
EE9400182A (et) Peptiidühendid, nende kasutamine, valmistamismeetod ja farmatseutiline segu
LV10263A (lv) 3- un 5- Aizvietoti 1,2,3,4-oksatriazol-5-amina savienojumi to iegusanas metode tos satuross farmaceitisks to preparats un ti izmantosana medikamentu iegusanai
IT1231458B (it) Composizioni dentifricie e metodo per la loro preparazione
BE885586A (fr) Nouveaux derives d'acides alcanoiques utiles notamment comme medicaments diuretiques, compositions therapeutiques et formes pharmaceutiques les contenant

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FA8 Dismissal: dismissal - article 36, par. 1 of industrial property law